On February 13, 2025 RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, reported its recent abstract presentation at the 2025 Society of Interventional Oncology Annual Conference ("SIO 2025") in Las Vegas, Nevada (Press release, Renovorx, FEB 13, 2025, View Source [SID1234650273]). The abstract published promising pre-clinical data from the use of RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which aims to optimize local and targeted drug delivery in difficult-to-treat cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled "Micro-CT imaging following intra-arterial delivery of a radiopaque silicone polymer using a double-balloon occlusion catheter in pigs: a model to analyze tissue penetration via the trans-arterial micro perfusion (TAMP) technique," was presented at SIO 2025 on February 3, 2025 by Paula Novelli, MD, of the University of Pittsburgh Medical Center.

The results of the study support a more optimized drug delivery method for tumors that suffer from limited blood supply and poor drug penetration. The TAMP technique was evaluated in a porcine (pig) model utilizing micro-CT imaging for precise monitoring of drug penetration into tissue.

The pre-clinical data shows that drug delivery with the patented, FDA-cleared dual balloon RenovoCath device via TAMP potentially may improve localized drug delivery by achieving greater drug penetration in the microvasculature near the target tumor. The data shows that, by using RenovoCath, researchers were able to isolate sections of the blood vessel through the adjustment of the distance between the occlusion balloons, thereby excluding any off-target side branches. Researchers were able to confirm the level of penetration into the targeted area utilizing micro-CT imaging. The penetration achieved appears to be consistent with a more optimized drug delivery. The observed effect is expected to be even stronger if radiation is applied beforehand.

"This study highlights that TAMP is an encouraging approach for improving localized drug delivery to difficult-to-treat tumor areas. By understanding how the infusion medium penetrates tissue, techniques can be refined for better clinical outcomes, especially for patients with cancers like pancreatic adenocarcinoma," said Dr. Ramtin Agah, RenovoRx’s Founder, Chairman of the Board and Chief Medical Officer and one of the study’s authors. "We look forward to continued research in hypovascular tumors using minimally invasive procedures and are also working on a radiation sub-study. With continued investigation, we believe TAMP has the potential to revolutionize how interventional oncologists approach cancer treatment, offering a more targeted, effective solution for challenging cases."

The procedure in this study utilized a porcine model, where the RenovoCath device was effectively employed to deliver a technique involved inflating the catheter balloons in the splenic artery, the superior mesenteric artery and renal artery. This approach enabled precise side branch exclusion in both vascular regions, ensuring targeted and controlled intervention, allowing for extensive filling of the microvessels with Microfil (a micro-CT imaging following an injection of a radiopaque silicone rubber imaging reagent) in the perivascular space. In comparison, the control group, where balloons in the splenic arteries were left deflated, showed minimal Microfil filling beyond the main artery, as confirmed by micro-CT imaging. These striking differences highlight the potential of this technique to drive forward the development of targeted therapies, especially for complex cancers like pancreatic adenocarcinoma.

"We are excited to highlight this pre-clinical data abstract presented at SIO 2025. Including procedures performed as part of clinical trials, intra-arterial drug delivery by RenovoCath has been used in over 500 procedures by oncologists and interventional radiologists over the past several years," said Shaun Bagai, RenovoRx CEO.

Mr. Bagai added, "Based on recent positive feedback we have received from medical practitioners, we have launched an effort to commercialize RenovoCath as a stand-alone device within its FDA-cleared indications for use in temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion."

Additionally, the TAMP therapy platform was the topic of the SIO 2025 panel discussion "Breaking Barriers in Drug Delivery: Trans-Arterial Micro-Perfusion," where key interventional oncologists including Dr. Novelli, Khashayar Farsad, MD, PhD, Oregon Health and Science University, and David Sperling, MD, FSIR, Columbia University Irving Medical Center discussed their experience with the therapy platform and the RenovoCath device.

About RenovoCath

Based on its FDA clearance, RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ("IFU"), please see: IFU-10004-Rev.-F-Universal-IFU.pdf.